JP2025515484A - Ｋｉｆ１８ａを阻害するための化合物 - Google Patents

Ｋｉｆ１８ａを阻害するための化合物 Download PDF

Info

Publication number
JP2025515484A
JP2025515484A JP2024563541A JP2024563541A JP2025515484A JP 2025515484 A JP2025515484 A JP 2025515484A JP 2024563541 A JP2024563541 A JP 2024563541A JP 2024563541 A JP2024563541 A JP 2024563541A JP 2025515484 A JP2025515484 A JP 2025515484A
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
cycloalkyl
pharma
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024563541A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025515484A5 (enExample
Inventor
エー． コーガン，デレク
Original Assignee
ヴォラストラ セラピューティクス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴォラストラ セラピューティクス，インコーポレーテッド filed Critical ヴォラストラ セラピューティクス，インコーポレーテッド
Publication of JP2025515484A publication Critical patent/JP2025515484A/ja
Publication of JP2025515484A5 publication Critical patent/JP2025515484A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024563541A 2022-04-28 2023-04-27 Ｋｉｆ１８ａを阻害するための化合物 Pending JP2025515484A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263336183P 2022-04-28 2022-04-28
US63/336,183 2022-04-28
US202263389237P 2022-07-14 2022-07-14
US63/389,237 2022-07-14
US202363456342P 2023-03-31 2023-03-31
US63/456,342 2023-03-31
PCT/US2023/020268 WO2023212240A1 (en) 2022-04-28 2023-04-27 Compounds for inhibiting kif18a

Publications (2)

Publication Number Publication Date
JP2025515484A true JP2025515484A (ja) 2025-05-15
JP2025515484A5 JP2025515484A5 (enExample) 2026-05-11

Family

ID=86604316

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024563541A Pending JP2025515484A (ja) 2022-04-28 2023-04-27 Ｋｉｆ１８ａを阻害するための化合物

Country Status (11)

Country Link
US (1) US20230382889A1 (enExample)
EP (1) EP4514790A1 (enExample)
JP (1) JP2025515484A (enExample)
KR (1) KR20250021398A (enExample)
CN (1) CN119451951A (enExample)
AU (1) AU2023261964A1 (enExample)
CA (1) CA3256989A1 (enExample)
IL (1) IL316450A (enExample)
MX (1) MX2024013215A (enExample)
TW (1) TW202346288A (enExample)
WO (1) WO2023212240A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211475A1 (es) 2018-12-20 2021-08-05 Amgen Inc Inhibidores de kif18a
WO2023028564A1 (en) 2021-08-26 2023-03-02 Volastra Therapeutics, Inc. Spiro indoline inhibitors of kif18a
AU2023254325A1 (en) * 2022-04-15 2024-10-17 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company Kif18a inhibitor and use thereof
WO2024039829A1 (en) 2022-08-18 2024-02-22 Accent Therapeutics, Inc. Inhibitors of kif18a and uses thereof
WO2025020624A1 (zh) * 2023-07-25 2025-01-30 捷思英达控股有限公司 一种苯环衍生物、其制备方法及其在医药上的应用
WO2025036479A1 (zh) * 2023-08-16 2025-02-20 上海湃隆生物科技有限公司 驱动蛋白kif18a抑制剂及其应用
WO2025090640A1 (en) 2023-10-23 2025-05-01 Volastra Therapeutics, Inc. Solid formulations and polymorphic forms of indoline inhibitors of kif18a
WO2025247067A1 (zh) * 2024-05-29 2025-12-04 上海复星医药产业发展有限公司 Kif18A抑制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
CA3123227A1 (en) * 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
MX2021007157A (es) * 2018-12-20 2021-08-16 Amgen Inc Heteroarilamidas utiles como inhibidores de kif18a.
US12540129B2 (en) * 2019-08-02 2026-02-03 Amgen Inc. KIF18A inhibitors
CN114302880B (zh) * 2019-08-02 2025-07-15 美国安进公司 Kif18a抑制剂
CA3224249A1 (en) * 2021-06-25 2022-12-29 Hangzhou Innogate Pharma Co., Ltd. Compound as kif18a inhibitor

Also Published As

Publication number Publication date
EP4514790A1 (en) 2025-03-05
IL316450A (en) 2024-12-01
WO2023212240A1 (en) 2023-11-02
MX2024013215A (es) 2024-12-06
CA3256989A1 (en) 2023-11-02
TW202346288A (zh) 2023-12-01
US20230382889A1 (en) 2023-11-30
AU2023261964A1 (en) 2024-11-07
KR20250021398A (ko) 2025-02-12
CN119451951A (zh) 2025-02-14

Similar Documents

Publication Publication Date Title
US20230382889A1 (en) Compounds for inhibiting kif18a
CN117964573B (zh) 作为心肌节抑制剂的二氢苯并呋喃和茚类似物
CN112707893B (zh) 作为usp30抑制剂的1-氰基吡咯烷化合物
JP2017508766A (ja) ＴｒｋＡキナーゼ阻害薬、その組成物および方法
US9586956B2 (en) Isoquinoline and naphthyridine derivatives
AU2022334480A1 (en) Spiro indoline inhibitors of kif18a
SG11202108792WA (en) Substituted bicyclic compounds as farnesoid x receptor modulators
JP5345931B2 (ja) ピリミドジアゼピノン誘導体
JP2010520205A (ja) 細菌性感染症の治療のための抗菌性複素環化合物
TW202440091A (zh) Ｎａｍｐｔ調節劑
JP2019001715A (ja) 三環性化合物
EP4463452B1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
JP7742850B2 (ja) フェロポルチン阻害剤としてのシクロアルキルピリミジン
KR20230155834A (ko) Ido/tdo 이중 저해용 화합물 및 이를 포함하는 약학적 조성물
JP2025510009A (ja) Ｒｉｐ１調節物質、その調製、及び使用
EA047337B1 (ru) Замещенные бициклические соединения в качестве модуляторов фарнезоидного х-рецептора
HK40011511B (en) Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260427